Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

DulaglutidevsTirzepatide

Once-weekly GLP-1 receptor agonist Fc-fusion protein (Trulicity) that reduces HbA1c by 1.5–1.9%, promotes 3–4.6 kg weight loss, and demonstrated cardiovascular event reduction in the REWIND trial — available in convenient pre-filled autoinjector with no reconstitution required

The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.

Weight ManagementWeight Management

At a Glance

Quick
comparison

Dose Range

Dulaglutide

0.75–4.5 mg

Tirzepatide

2.5–15 mg

Frequency

Dulaglutide

Once weekly

Tirzepatide

Once weekly

Administration

Dulaglutide

Subcutaneous injection

Tirzepatide

Subcutaneous injection

Cycle Length

Dulaglutide

Ongoing/indefinite

Tirzepatide

Ongoing/indefinite

Onset Speed

Dulaglutide

Gradual (3-4 weeks)

Tirzepatide

Moderate (1-2 weeks)

Evidence Level

Dulaglutide

Strong human trials (Phase 3 or FDA approved)

Tirzepatide

Strong human trials (Phase 3 or FDA approved)

Efficacy

Benefit
ratings

Dulaglutide
Tirzepatide

Metabolic

Dulaglutide9%
Tirzepatide0%

Weight Management

Dulaglutide8%
Tirzepatide0%

Healing & Recovery

Dulaglutide8%
Tirzepatide0%

Weight Loss

Dulaglutide0%
Tirzepatide99%

Appetite Control

Dulaglutide0%
Tirzepatide97%

Blood Sugar Control

Dulaglutide0%
Tirzepatide96%

Technical Data

Compound
specifications

Dulaglutide

Molecular Formula

C2646H4044N704O836S18 (complete fusion protein homodimer)

Molecular Weight

~63 kDa (~59,670 Da per chain)

Half-Life

~5 days (terminal elimination); Tmax ~48 hours; steady state in 2–4 weeks; accumulation ratio 1.56 at 1.5 mg

Bioavailability

47–65% after subcutaneous injection (dose-dependent); apparent clearance 0.142 L/h

CAS Number

923950-08-7

Tirzepatide

Molecular Formula

C225H348N48O68

Molecular Weight

4813.45 g/mol

Half-Life

Approximately 5 days (120 hours)

Bioavailability

~80% (subcutaneous)

CAS Number

2023788-19-2

Protocols

Dosing
tiers

Dulaglutide

starting

0.75 mg subcutaneous once weekly

Once weekly

4 weeks minimum (tolerability assessment)

Initiate at 0.75 mg weekly to assess gastrointestinal tolerability. Inject in abdomen, thigh, or upper arm on the same day each week — timing can be changed as long as the last dose was at least 3 days prior. No reconstitution required; use the pre-filled autoinjector pen. If combining with insulin or sulfonylureas, consider reducing their dose to minimize hypoglycemia.

standard

1.5 mg subcutaneous once weekly

Once weekly

Ongoing chronic therapy

Standard maintenance dose for most type 2 diabetes patients. Increase from 0.75 mg after at least 4 weeks if additional glycemic control is needed. This dose provides HbA1c reduction of approximately 1.5% and weight loss of 3.0 kg. The ready-to-use autoinjector pen simplifies administration. No dose adjustment needed for renal or hepatic impairment.

advanced

3.0–4.5 mg subcutaneous once weekly

Once weekly

Ongoing chronic therapy

Higher doses approved in 2020 for patients requiring additional glycemic control. AWARD-11 demonstrated 4.5 mg superiority over 1.5 mg: HbA1c -1.77% vs -1.54% and weight loss -4.6 kg vs -3.0 kg. Titrate from 1.5 mg to 3.0 mg and then to 4.5 mg at minimum 4-week intervals. GI side effects are dose-dependent but generally tolerable with gradual escalation.

Tirzepatide

starting

2.5 mg

Once weekly

4 weeks

This introductory dose helps your body adjust to the medication and minimizes GI side effects. Don't expect much weight loss yet—this phase is all about building tolerance. Think of it as your body's training wheels period.

standard

5-10 mg

Once weekly

4+ weeks at each dose

After 4 weeks at 2.5mg, increase to 5mg. Stay here for at least 4 weeks, then move to 7.5mg, then 10mg. This gradual climb reduces side effects while ramping up the weight loss. Most people start seeing serious results at 5-10mg doses.

advanced

12.5-15 mg

Once weekly

Ongoing/maintenance

The 15mg dose delivers maximum weight loss—averaging over 20% of body weight in trials. Continue increasing by 2.5mg every 4 weeks until reaching 15mg or your optimal maintenance dose. This is where the jaw-dropping results happen.

Applications

Best
suited for

Dulaglutide

Type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control

Dulaglutide is particularly well-suited for individuals focused on type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Patients with established cardiovascular disease or multiple CV risk factors seeking REWIND-proven cardioprotection

Dulaglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or multiple cv risk factors seeking rewind-proven cardioprotection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Overweight or obese T2DM patients requiring both weight loss and HbA1c reduction

Dulaglutide is particularly well-suited for individuals focused on overweight or obese t2dm patients requiring both weight loss and hba1c reduction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Pediatric patients aged 10–17 with type 2 diabetes (approved indication)

Dulaglutide is particularly well-suited for individuals focused on pediatric patients aged 10–17 with type 2 diabetes (approved indication). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Tirzepatide

People Who Want Maximum Weight Loss Results

If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close.

Those Who Haven't Succeeded with Semaglutide

Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss.

People with Type 2 Diabetes Needing Aggressive Control

Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health.

Individuals Looking to Transform Their Relationship with Food

Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you.

Safety Profile

Side
effects

Dulaglutide

Common

  • Nausea
  • Diarrhea and abdominal pain
  • Vomiting
  • Decreased appetite

Uncommon

  • Injection site reactions and fatigue

Serious

  • Acute pancreatitis
  • Gallbladder disease

Tirzepatide

Common

  • Nausea
  • Diarrhea
  • Decreased Appetite
  • Vomiting

Uncommon

  • Gallbladder Problems
  • Hair Thinning (Telogen Effluvium)

Serious

  • Pancreatitis
  • Thyroid Tumors (Theoretical Risk)

Research Status

Safety
& evidence

Dulaglutide

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Dulaglutide is an FDA-approved GLP-1 receptor agonist carrying a black box warning for thyroid C-cell tumor risk, based on rodent data showing increased medullary thyroid cancer (MTC) in rat models. This risk is contraindicated in patients with personal or family history of MTC or multiple endocrine neoplasia type 2. Nausea occurs in 20-40% of patients, particularly dose-dependent and most severe at initiation; gastrointestinal side effects (vomiting, diarrhea) are common. Pancreatitis has been reported in 0.1-0.2% of patients—discontinue immediately if severe abdominal pain develops. Rapid weight loss can trigger gallstone formation. Dehydration risk is significant, especially with concurrent SGLT2 inhibitors. Injection site reactions are mild but frequent.

Contraindications

  • xPersonal or family history of medullary thyroid carcinoma (MTC) — black box warning based on rodent thyroid C-cell tumor data
  • xMultiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • xKnown serious hypersensitivity to dulaglutide or any excipient
  • xType 1 diabetes mellitus or diabetic ketoacidosis (not indicated)

Tirzepatide

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. The FDA approved it after thorough safety review. While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes.

Contraindications

  • xPersonal or family history of medullary thyroid carcinoma (MTC)
  • xMultiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • xHistory of serious allergic reaction to tirzepatide or any GLP-1/GIP medication
  • xCurrent or recent pancreatitis
  • xPregnancy or planning to become pregnant

Decision Guide

Which is
right for you?

Choose Dulaglutide if...

  • Type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control
  • Patients with established cardiovascular disease or multiple CV risk factors seeking REWIND-proven cardioprotection
  • Overweight or obese T2DM patients requiring both weight loss and HbA1c reduction
  • Pediatric patients aged 10–17 with type 2 diabetes (approved indication)

Choose Tirzepatide if...

  • Maximum weight loss results
  • Long-term obesity management
  • Type 2 diabetes control
  • Metabolic health improvement